Artículos del autor

solaci

Day 2

Global Registry SYMPLICITY demonstrated the safety of renal denervation system

The Global SYMPLICITY registry is a prospective, multicenter study sponsored by Medtronic to evaluate long- term renal...
solaci -
Day 2

GAUSS -2: Evolocumab effective in reducing LDL cholesterol in patients intolerant to statins

Adverse effects of statins are relatively common causing poor adherence to treatment and the need for interruption...
solaci -
Day 2

ALECARDIO Trial: Aleglitazar associated with severe adverse events in diabetic patients with acute coronary syndrome

This randomized, double-blind, placebo-controlled, multicenter work evaluated the potential cardiovascular reduction risk and the long-term safety profile...
solaci -
Day 2

MADIT -CRT: Increased survival with resynchronization therapy plus defibrillator in patients with mild heart failure.

The MADIT -CRT study (Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy) had shown that early intervention...
solaci -
Day 2

CHOICE Trial: Same mortality, less aortic regurgitation and need for a second prosthetic for Edwards Sapien XT valve versus Medtronic CoreValve

So far, there had been no published randomized studies comparing balloon-expandable Edwards’s prosthesis and self-expandingCoreValve. The aim...
solaci -
Day 3

COAG Trial: Dose of warfarin and Pharmacogenetics

Observational studies identified two genes that influence the dose of warfarin (CYP2C9 and VKORC1). The clinical utility...
solaci -
Day 2

STABILITY Trial: Daraplabid no benefits in chronic coronary artery disease

Daraplabid is a selective oral inhibitor of lipoprotein-associated phospholipase (Lp -PLA2)which is a potential agent for reducing...
solaci -
Day 1

CoreValve superior to surgical aortic valve replacement in high-risk patients

The aim of this study was to compare percutaneous aortic valve replacement (TAVR) with the self-expanding Valve...
solaci -